In the last 20 years, increasing data have corroborated initial evidence that DCs (or specific subsets thereof) can acquire functional, preformed p‐MHC complexes from cancer cells to prime both CD4+ and CD8+ T cells against cancer. The gene discussed is CD8A; the disease is cancer.